TheraRadar
← Back
Data updated: Mar 29, 2026

MARKSANS PHARMA

ImmunologyInfectious DiseaseCardiovascular
Generics

MARKSANS PHARMA is a generic drug manufacturer focused on Immunology, Infectious Disease, Cardiovascular.

2002
Since
16
Drugs
-
Trials
285
Approved (2yr)

Key Drugs

ACETAMINOPHEN AND IBUPROFEN
acetaminophen
· 2023

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

GABAPENTIN 2026-02-24
Labeling
GABAPENTIN 2026-02-18
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-12
Labeling
CETIRIZINE HYDROCHLORIDE ALLERGY 2026-01-30
Labeling
GABAPENTIN 2026-01-29
Labeling
GABAPENTIN 2026-01-29
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 25%
1 drugs
Infectious Disease 25%
1 drugs
Cardiovascular 25%
1 drugs
Gastroenterology 25%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Immunology, Gastroenterology
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
Johnson & Johnson big-pharma
Immunology, Infectious Disease, Cardiovascular
Bristol-Myers Squibb big-pharma
Immunology, Gastroenterology, Infectious Disease
QUAGEN specialty
Gastroenterology, Cardiovascular, Infectious Disease, Immunology